Sign up to save your podcasts
Or
Share GU ASCO 2025 Highlights - TALAPRO-2, NIAGARA, CheckMate-9ER, TiNivo-2
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
GU ASCO 2025 Highlights - TALAPRO-2, NIAGARA, CheckMate-9ER, TiNivo-2
Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Toni Choueiri, a leading GU medical oncologist from Dana-Farber Cancer Institute. Together, they dive into the highlights from the GU ASCO 2025 conference, covering key studies and updates in the world of genitourinary oncology.
Episode Highlights:
• TALAPRO-2: An in-depth discussion on the role of PARP inhibitors in prostate cancer, focusing on the study's design, findings, and the importance of germline and NGS testing.
• NIAGARA Update: Insights into the new standard of care for resectable muscle-invasive bladder cancer and the promising results from the perioperative approach with Durvalumab.
• CheckMate-9ER Update: A look at the combination of Cabozantinib and Nivolumab in first-line metastatic RCC, including the latest findings and implications for treatment beyond the first line.
• TiNivo2: Exploring the role of Tivozanib in the treatment landscape of RCC and potential sequencing strategies.
Join us for this informative discussion that aims to keep community oncologists up to date with the latest advancements in cancer care. If you find this episode helpful, please share it with your colleagues and leave us a review!
YouTube: https://youtu.be/OzeHhyAdF9Q
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to subscribe for more insights and updates from the Oncology Brothers!
View all episodes
By Oncology Brothers
4.8
3939 ratings
Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Toni Choueiri, a leading GU medical oncologist from Dana-Farber Cancer Institute. Together, they dive into the highlights from the GU ASCO 2025 conference, covering key studies and updates in the world of genitourinary oncology.
Episode Highlights:
• TALAPRO-2: An in-depth discussion on the role of PARP inhibitors in prostate cancer, focusing on the study's design, findings, and the importance of germline and NGS testing.
• NIAGARA Update: Insights into the new standard of care for resectable muscle-invasive bladder cancer and the promising results from the perioperative approach with Durvalumab.
• CheckMate-9ER Update: A look at the combination of Cabozantinib and Nivolumab in first-line metastatic RCC, including the latest findings and implications for treatment beyond the first line.
• TiNivo2: Exploring the role of Tivozanib in the treatment landscape of RCC and potential sequencing strategies.
Join us for this informative discussion that aims to keep community oncologists up to date with the latest advancements in cancer care. If you find this episode helpful, please share it with your colleagues and leave us a review!
YouTube: https://youtu.be/OzeHhyAdF9Q
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to subscribe for more insights and updates from the Oncology Brothers!
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
NEJM This Week
321 Listeners
Journal of Clinical Oncology (JCO) Podcast
42 Listeners
Research To Practice | Oncology Videos
111 Listeners
JAMA Clinical Reviews
502 Listeners
ASCO Daily News
60 Listeners
Core IM | Internal Medicine Podcast
1,110 Listeners
OncoPharm
182 Listeners
ASCO Guidelines
45 Listeners
OncLive® On Air
22 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
360 Listeners
Lung Cancer Considered
28 Listeners
The Passive Income MD Podcast
277 Listeners
Oncology Today with Dr Neil Love
60 Listeners
Two Onc Docs
181 Listeners
Blood Cancer Talks
48 Listeners